CN110177771B - 用于治疗、预防或改善非酒精性脂肪肝病(NAFLD)、NASH、ALD或肝相关病状的γ-酮醛清除剂的组合物和使用方法 - Google Patents

用于治疗、预防或改善非酒精性脂肪肝病(NAFLD)、NASH、ALD或肝相关病状的γ-酮醛清除剂的组合物和使用方法 Download PDF

Info

Publication number
CN110177771B
CN110177771B CN201780064767.2A CN201780064767A CN110177771B CN 110177771 B CN110177771 B CN 110177771B CN 201780064767 A CN201780064767 A CN 201780064767A CN 110177771 B CN110177771 B CN 110177771B
Authority
CN
China
Prior art keywords
liver
hoba
nash
liver disease
alcoholic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780064767.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110177771A (zh
Inventor
J·拉特马克
N·阿布莱德
C·弗林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiyuan Group Co ltd
Original Assignee
Metabolic Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Technologies LLC filed Critical Metabolic Technologies LLC
Priority to CN202211453642.8A priority Critical patent/CN119345198A/zh
Publication of CN110177771A publication Critical patent/CN110177771A/zh
Application granted granted Critical
Publication of CN110177771B publication Critical patent/CN110177771B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pediatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780064767.2A 2016-09-06 2017-09-06 用于治疗、预防或改善非酒精性脂肪肝病(NAFLD)、NASH、ALD或肝相关病状的γ-酮醛清除剂的组合物和使用方法 Active CN110177771B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211453642.8A CN119345198A (zh) 2016-09-06 2017-09-06 包含γ-酮醛清除剂的组合物及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662383895P 2016-09-06 2016-09-06
US62/383,895 2016-09-06
US201662410133P 2016-10-19 2016-10-19
US62/410,133 2016-10-19
PCT/US2017/050317 WO2018048932A1 (en) 2016-09-06 2017-09-06 Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211453642.8A Division CN119345198A (zh) 2016-09-06 2017-09-06 包含γ-酮醛清除剂的组合物及其用途

Publications (2)

Publication Number Publication Date
CN110177771A CN110177771A (zh) 2019-08-27
CN110177771B true CN110177771B (zh) 2022-12-13

Family

ID=61562136

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780064767.2A Active CN110177771B (zh) 2016-09-06 2017-09-06 用于治疗、预防或改善非酒精性脂肪肝病(NAFLD)、NASH、ALD或肝相关病状的γ-酮醛清除剂的组合物和使用方法
CN202211453642.8A Pending CN119345198A (zh) 2016-09-06 2017-09-06 包含γ-酮醛清除剂的组合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211453642.8A Pending CN119345198A (zh) 2016-09-06 2017-09-06 包含γ-酮醛清除剂的组合物及其用途

Country Status (8)

Country Link
US (3) US20180153827A1 (https=)
EP (1) EP3510014B1 (https=)
JP (3) JP7189127B2 (https=)
CN (2) CN110177771B (https=)
AU (1) AU2017324935B2 (https=)
CA (1) CA3035897A1 (https=)
MX (1) MX2019002579A (https=)
WO (1) WO2018048932A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201074A1 (en) * 2017-04-27 2018-11-01 Vanderbilt University Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers
BR112020004372A2 (pt) * 2017-09-05 2020-09-08 Mti Biotech, Inc. método para tratar, prevenir ou melhorar fibrose hepática em um indivíduo.
PL3914359T3 (pl) 2019-01-25 2025-07-28 Mti Biotech, Inc. Pochodne salicyloaminy przyłączone do trifenylofosfonium
CN114344448A (zh) * 2022-01-20 2022-04-15 广西医科大学第一附属医院 Pmx-53多肽在制备治疗非酒精性脂肪性肝炎药物中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1628650A (zh) * 2003-12-19 2005-06-22 刘力 复方二氯醋酸二异丙胺冻干粉针制剂及其制备方法
WO2008070778A2 (en) * 2006-12-06 2008-06-12 Nephrogenex Inc. Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
CN102065847A (zh) * 2008-04-29 2011-05-18 韩诺生物制约株式会社 含有血管紧张素-ⅱ受体阻断剂的药物制剂
WO2013168013A2 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic diseases and inflammatory disorders
CN103796648A (zh) * 2011-07-12 2014-05-14 范德比尔特大学 用γ-醛酮清除剂治疗炎症和高血压的方法
WO2016077279A1 (en) * 2014-11-11 2016-05-19 Vanderbilt University Methods for limiting acute kidney injury
WO2017033119A1 (en) * 2015-08-25 2017-03-02 Rao M Surya Compositions and methods for the treatment of liver metabolic diseases
CN111225666A (zh) * 2017-09-05 2020-06-02 Mti生物技术公司 用于治疗、预防或改善肝纤维化的γ-酮醛清除剂的组合物和使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2197689T3 (es) * 1998-10-22 2004-01-01 University Of South Carolina Procedimientos para inhibir complicaciones diabeticas.
EP1177796B1 (en) * 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Medicament for prevention or therapeutic treatment of liver disease
US8822542B2 (en) * 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
US20150265584A1 (en) * 2014-03-18 2015-09-24 Vanderbilt University Levuglandin adducts histone h4 in a cyclooxygenase-2-dependent manner, altering its interaction with dna
US20210023032A1 (en) * 2017-09-05 2021-01-28 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1628650A (zh) * 2003-12-19 2005-06-22 刘力 复方二氯醋酸二异丙胺冻干粉针制剂及其制备方法
WO2008070778A2 (en) * 2006-12-06 2008-06-12 Nephrogenex Inc. Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
CN102065847A (zh) * 2008-04-29 2011-05-18 韩诺生物制约株式会社 含有血管紧张素-ⅱ受体阻断剂的药物制剂
CN103796648A (zh) * 2011-07-12 2014-05-14 范德比尔特大学 用γ-醛酮清除剂治疗炎症和高血压的方法
WO2013168013A2 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic diseases and inflammatory disorders
WO2016077279A1 (en) * 2014-11-11 2016-05-19 Vanderbilt University Methods for limiting acute kidney injury
WO2017033119A1 (en) * 2015-08-25 2017-03-02 Rao M Surya Compositions and methods for the treatment of liver metabolic diseases
CN111225666A (zh) * 2017-09-05 2020-06-02 Mti生物技术公司 用于治疗、预防或改善肝纤维化的γ-酮醛清除剂的组合物和使用方法

Also Published As

Publication number Publication date
MX2019002579A (es) 2020-02-05
WO2018048932A1 (en) 2018-03-15
EP3510014A4 (en) 2020-05-20
AU2017324935B2 (en) 2021-10-21
JP2025032245A (ja) 2025-03-11
EP3510014B1 (en) 2026-04-29
JP2023022236A (ja) 2023-02-14
US20180153827A1 (en) 2018-06-07
CN119345198A (zh) 2025-01-24
US12383515B2 (en) 2025-08-12
JP7189127B2 (ja) 2022-12-13
EP3510014A1 (en) 2019-07-17
US20230181494A1 (en) 2023-06-15
CN110177771A (zh) 2019-08-27
CA3035897A1 (en) 2018-03-15
AU2017324935A1 (en) 2019-03-28
BR112019004404A2 (pt) 2019-05-28
JP2019526598A (ja) 2019-09-19
US20250360094A1 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
US12383515B2 (en) Compositions and methods of use of γ-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (NAFLD), NASH, ALD or conditions related to the liver
Videla et al. Perspectives in liver redox imbalance: toxicological and pharmacological aspects underlying iron overloading, nonalcoholic fatty liver disease, and thyroid hormone action
Mostafa-Hedeab et al. A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19
Song et al. Silymarin protects against acute ethanol‐induced hepatotoxicity in mice
Niu et al. Protective effect of gentiopicroside against dextran sodium sulfate induced colitis in mice
Ye et al. Theaflavin protects against oxalate calcium-induced kidney oxidative stress injury via upregulation of SIRT1
CN111182904A (zh) 包含acc抑制剂的组合治疗
Angoa-Pérez et al. Effects of combined treatment with mephedrone and methamphetamine or 3, 4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus
Ahmed et al. Paracetamol overdose induces acute liver injury accompanied by oxidative stress and inflammation
Sharawy et al. Anti-fibrotic activity of sitagliptin against concanavalin A-induced hepatic fibrosis. Role of Nrf2 activation/NF-κB inhibition
Chen et al. Depression by a green tea extract of alcohol-induced oxidative stress and lipogenesis in rat liver
El-Gazar et al. Elucidating PAR1 as a therapeutic target for delayed traumatic brain injury: Unveiling the PPAR-γ/Nrf2/HO-1/GPX4 axis to suppress ferroptosis and alleviate NLRP3 inflammasome activation in rats
Abd-Allah et al. Biological and pharmacological characterization of ascorbic acid and nicotinamide chitosan nanoparticles against insulin-resistance-induced cognitive defects: a comparative study
KR20060129082A (ko) 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과연관된 질환 또는 질병의 치료 방법
Guo et al. Overexpression of aldehyde dehydrogenase‐2 attenuates chronic alcohol exposure‐induced apoptosis, change in Akt and Pim signalling in liver
Han et al. Protective effects of facilitated removal of blood alcohol and acetaldehyde against liver injury in animal models fed alcohol and anti‐HIV drugs
Tang et al. Sodium butyrate attenuates liver fibrogenesis via promoting H4K8 crotonylation
HK40012573B (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver
HK40012573A (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver
BR112019004404B1 (pt) Uso de um composto
CN114470217B (zh) 预防和治疗代谢异常或炎症引起的组织损伤的药物组合物
Liu et al. Schisandrin c improves chronic Stress-Induced dyslipidemia in mice by regulating pyroptosis and autophagy levels
Lee et al. Parapyruvate induces neurodegeneration in C57BL/6JNarl mice via Inhibition of the α-ketoglutarate dehydrogenase complex
TW201418280A (zh) 甘胺酸ｎ－甲基轉移酵素（ｇｎｍｔ）用於治療或預防脂肪肝病
Afzal et al. Pharmacological evaluation of gatifloxacin in chemically induced hepatocarcinogenesis: A new tool for hepatocellularcarcinoma treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40012573

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20250519

Address after: 214400 Jiangsu Province Wuxi City Jiangyin Port Economic Development Zone Jinxiu Road No. 2

Patentee after: Jiyuan Group Co.,Ltd.

Country or region after: China

Address before: Iowa, USA

Patentee before: METABOLIC TECHNOLOGIES, Inc.

Country or region before: U.S.A.

TR01 Transfer of patent right